Shenzhen Aima Biotechnology (ExoRNA Bio)

Shenzhen Aima Biotechnology (ExoRNA Bio), established in September 2021, is a biopharmaceutical company specializing in nucleic acid drug development. The company was co-founded by Professor Zhang Chenyu, a distinguished scholar in extracellular RNA research from Nanjing University, and Dr. Meng Xia, who has extensive experience in R&D and management at multinational biotech firms. Professor Zhang is recognized for discovering that miRNA can exist stably outside cells within exosomes, pioneering a new field of research. Dr. Meng holds a Ph.D. from the University of Paris VI and has over a decade of research experience at the French National Institute of Medical Sciences and the Curie Institute.

ExoRNA Bio's core technology is a proprietary in-vivo self-assembling exosome nucleic acid drug delivery platform. This platform addresses significant challenges in RNA drug delivery by enabling therapeutics to cross the blood-brain barrier and target multiple organs with high safety and lower cost. The company's approach uses the body's own tissues as bioreactors to process and package siRNA into endogenous exosomes, ensuring biocompatibility and protecting the therapeutic payload. The primary focus is on developing treatments for diseases with high unmet clinical needs, particularly those affecting the central nervous system (CNS), such as Huntington's disease, as well as anti-viral and anti-superbug drugs. Its first R&D pipeline candidate, ER-2001, targets Huntington's disease.

The company operates a platform-based business model, concentrating on the research and development of its innovative drug delivery system and associated nucleic acid therapeutics. Headquartered in Shenzhen, ExoRNA Bio has established subsidiaries in Nanjing and Shanghai to support its R&D and operational activities. The company has secured funding from investors including CDH Investments, Dingxin Capital, and Yuexiu Financial Holdings to advance its pipeline.

Keywords: exosome therapeutics, nucleic acid drugs, RNA drug delivery, central nervous system diseases, blood-brain barrier, siRNA, biotechnology, drug discovery, Huntington's disease, in-vivo self-assembly, organ targeting, gene therapy, extracellular RNA, biopharmaceutical, rare diseases, regenerative medicine, synthetic biology, liquid biopsy, drug development, neurological disorders